Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Plus Therapeutics Inc.
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
July 28, 2026
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
June 25, 2026
Plus Therapeutics to Provide Business Update Call on June 30, 2026
June 23, 2026
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 4, 2026
Plus’ CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
May 26, 2026
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
May 21, 2026
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
May 21, 2026
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
May 8, 2026
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
May 7, 2026
1
2
3
Next Page
→